Evidence map›Paper›PMID 29907142›Full record

ArticleBMC cancer2018

MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.

Hao Liu, Wang He, Bo Wang, Kewei Xu, Jinli Han, Junjiong Zheng, Jun Ren, Lin Shao, Shiping Bo, Sijia Lu and 2 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03998371 unknown statusnot on this mapstarted 2019, after this paper: background citation

Ultrasensitive Chromosomal Aneuploidy Detection (UCAD) in Urine Exfoliated Cells for Diagnosis of Urothelial Carcinoma in in Urine Exfoliated Cells

TypeobservationalSponsorChanghai HospitalRan2019 to 2020Enrolled300ConditionsUrothelial Carcinoma, Diagnoses Disease, Chromosomal Abnormality, Urine MarkingArmsLow-coverage whole-genome sequencing of urine exfoliated cells
NCT04432909 unknown statusnot on this mapstarted 2020, after this paper: background citation

A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up

TypeobservationalSponsorChanghai HospitalRan2020 to 2022Enrolled500ConditionsUrothelial CarcinomaArmsThe level of CNV
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hao LiuDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China.
Wang HeDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China.
Bo WangDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China.
Kewei XuDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China.
Jinli HanDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China.
Junjiong ZhengDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China.
Jun RenDepartment of Clinical Research, Yikon Genomics, 1698 Wangyuan Road, Building #26, Fengxian District, Shanghai, 201400, China.
Lin ShaoDepartment of Clinical Research, Yikon Genomics, 1698 Wangyuan Road, Building #26, Fengxian District, Shanghai, 201400, China.
Shiping BoDepartment of Clinical Research, Yikon Genomics, 1698 Wangyuan Road, Building #26, Fengxian District, Shanghai, 201400, China.
Sijia LuDepartment of Clinical Research, Yikon Genomics, 1698 Wangyuan Road, Building #26, Fengxian District, Shanghai, 201400, China. lusijia@yikongenomics.com.
Tianxin LinDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China. tianxinl@sina.com.
Jian HuangDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Guangzhou, China. Urolhj@sina.com.
Sun Yat-sen University · CNSun Yat-sen Memorial Hospital · CN

Funding

National Natural Science Foundation of China 81472384National Natural Science Foundation of China 81572514
6 · The paper itself

Abstract

backgroundThe gold standard for bladder cancer detection is cystoscopy, which is an invasive procedure that causes discomfort in patients. The currently available non-invasive approaches either show limited sensitivity in low-grade tumours or possess unsatisfying specificity. The aim of the present study is to develop a new non-invasive strategy based on chromosomal imbalance levels to detect bladder cancer effectively.

methodsWe enrolled 74 patients diagnosed with bladder cancer (BC), 51 healthy participants and 27 patients who were diagnosed with non-malignant urinary disease (UD). The Chromosomal Imbalance Analysis (CIA) was conducted in the tumours and urine of participants via the multiple annealing and looping-based amplification cycles-next-generation sequencing (MALBAC-NGS) strategy. The threshold of the CIA was determined with the receiver operating characteristic (ROC) curve. The comparison of the CIA with voided urine cytology was also performed in a subgroup of 55 BC patients. The consistency and discrepancy of the different assays were studied with the Kappa analysis and the McNemar test, respectively. The performance of the urinary CIA was also validated in an additional group of 120 BC patients, 15 UD and 45 healthy participants.

resultsGood concordance (87.0%) in the assessments of patient tumour tissues and urine was observed. The urine-based evaluation also demonstrated a good performance (accuracy = 89.0%, sensitivity = 83.1%, specificity = 94.5%, NPV = 85.4% and PPV = 93.7%; AUC = 0.917, 95%CI =0.868-0.966, P < 0.001) in the training group, particularly in the patients with CIA-positive tumours (accuracy = 92.7%, sensitivity = 89.8%). The sensitivity and specificity in the validation group were 89.2 and 90.0%, respectively. Even in Ta/T1 and low-grade tumour patients, the sensitivity was 85-90%. The CIA also exhibited a significantly improved sensitivity compared to voided urine cytology.

conclusionsThis is the first study employing the concept of whole genome imbalance combined with the MALBAC technique to detect bladder cancer in urine. MALBAC-CIA yielded significant diagnostic power, even in early-stage/low-grade tumour patients, and it may be used as a non-invasive approach for diagnosis and recurrence surveillance in bladder cancer prior to the use of cystoscopy, which would largely reduce the burden on patients.

Indexed as

AdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorChromosomal InstabilityFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedROC CurveSensitivity and SpecificityUrinary Bladder NeoplasmsBiomarkers, TumorBladder CancerChromosomal imbalance analysisCNVMALBACNGS

Identifiers

PMID29907142
PMCPMC6003132
OpenAlexW2808190430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.